SOLANA BEACH, Calif., Could 13, 2022 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Firm”), a world therapy-enabling platform firm offering navigation and supply to the mind, right this moment introduced it is going to current investigational analysis and exhibit on the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Washington, DC.
The analysis abstract to be introduced within the poster session, entitled AAV Vectors – Preclinical and Proof-of-Idea, will deal with classes discovered utilizing convection-enhanced supply to infuse gene remedy merchandise within the pre-clinical setting. Lead creator Dr. Ernesto Salegio, the Firm’s Vice President, Section Chief for Translational & Pre-Medical Analysis, will current the poster on Monday, Could 16th at 5:30 PM Jap Time. Convention attendees are welcome to attend the poster session in addition to go to the ClearPoint Neuro workforce in booth 373 throughout exhibit hours.
“Our workforce is proud to be first-time presenters at ASGCT,” commented Jeremy Stigall, Vice President of Biologics & Drug Supply at ClearPoint Neuro. “Our investigational analysis goals to display the feasibility and tolerability of utilizing ClearPoint expertise to focus on and ship gene remedy merchandise within the pre-clinical enviornment. Our work emphasizes the significance of real-time MRI visualization to watch vector transport and infusion patterns which can be distinctive to the cerebellum, and our knowledge gives issues that could be instantly translatable to the scientific trial packages of lots of our present and future biologics and drug supply companions.”
About ClearPoint Neuro
ClearPoint Neuro’s mission is to enhance and restore high quality of life to sufferers and their households by enabling therapies for probably the most complicated neurological problems with pinpoint accuracy. Purposes of the Firm’s present product portfolio embrace deep mind stimulation, laser ablation, biopsy, neuro-aspiration, and supply of medication, biologics, and gene remedy to the mind. The ClearPoint® Neuro Navigation System has FDA clearance, is CE-marked, and is put in in over 60 energetic websites in the USA, Canada, and Europe. ClearPoint Neuro is partnered with roughly 45 biologics/pharmaceutical corporations and tutorial facilities, offering options for direct CNS supply of therapeutics in pre-clinical research and scientific trials worldwide. Up to now, greater than 5,000 instances have been carried out and supported by the Firm’s field-based scientific specialist workforce, which presents assist and providers to our clients and companions worldwide. For extra info, please go to www.clearpointneuro.com
Statements herein in regards to the Firm’s plans, development and methods could embrace forward-looking statements inside the context of the federal securities legal guidelines. Statements concerning the Firm’s future occasions, developments and future efficiency, in addition to administration’s expectations, beliefs, plans, estimates or projections regarding the long run, are forward-looking statements inside the which means of those legal guidelines. Uncertainties and dangers could trigger the Firm’s precise outcomes to vary materially from these expressed in or implied by forward-looking statements. Specific uncertainties and dangers embrace these regarding: the impression of the COVID-19 pandemic and the measures adopted to comprise its unfold; future income from gross sales of the Firm’s ClearPoint Neuro Navigation System merchandise; the Firm’s capability to market, commercialize and obtain broader market acceptance for the Firm’s ClearPoint Neuro Navigation System merchandise; and dangers inherent within the analysis and improvement of recent merchandise. Extra detailed info on these and extra elements that might have an effect on the Firm’s precise outcomes are described within the “Threat Components” part of the Firm’s Annual Report on Type 10-Ok for the yr ended December 31, 2021, and the Firm’s Quarterly Report on Type 10-Q for the three months ended March 31, 2022, each of which have been filed with the Securities and Change Fee.